Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Combined with Apatinib and Chemotherapy for Unresectable Biliary Tract Carcinoma
NCT06749730Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab and Rivoceranib in biliary tract carcinoma (BTC), sponsored by Henan Cancer Hospital. Primary endpoint: Progression-free Survival. Started Apr 2024; status: recruiting.
02
Drugs
adebrelimabRivoceranib
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT06749730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06749730.